Xcellerex, Inc., Pfenex Inc. and Collaborators Complete Successful Test: Rapid Production of Swine Flu H1 Hemagglutinin

MARLBORO, Mass. and SAN DIEGO--(BUSINESS WIRE)--Xcellerex, Inc. and Pfenex Inc. announced today that the companies, along with deltaDOT Ltd. and BioPharm Services have successfully demonstrated the production of purified swine flu H1 hemagglutinin (California strain) in 42 days starting from the amino acid sequence of the protein. During that period, the gene was cloned and expressed, fermentation and purification processes developed, and the quality product shown to be fully within the specifications set out by the Defense Threat Reduction Agency (DTRA) under its Accelerated Manufacturing of Pharmaceuticals contract.

Back to news